Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

bimatoprost Ophthalmic Solution

A sterile ophthalmic solution containing 0.03% of a synthetic prostaglandin analog bimatoprost with hair-growing and anti-glaucoma activities… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Vitiligo is one of the commonest pigmentary disorders characterized by destruction of melanocytes. 
2013
2013
BACKGROUND The Food and Drug Administration has approved bimatoprost ophthalmic solution (0.03%) for the treatment of eyelash… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
2013
2013
BACKGROUND Hypotrichosis of the eyelashes may negatively influence an individual's self-perception and appearance. Assessing the… Expand
2012
2012
Purpose The aim of this study was to evaluate the efficacy and safety of bimatoprost ophthalmic solution 0.03% (bimatoprost) in… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
2011
2011
Background: Bimatoprost ophthalmic solution 0.03% was approved in the US for reducing intraoccular pressure (IOP) based on two… Expand
  • table 2
  • table 3
  • table 4
  • figure 1
2010
2010
PURPOSE To quantify the aqueous humor (AH) concentrations of bimatoprost (amide), travoprost (isopropyl ester), and their… Expand
2010
2010
  • S. Fagien
  • Clinical, cosmetic and investigational…
  • 2010
  • Corpus ID: 345756
Prominent eyelashes are generally recognized as enhancing beauty and are often desired by women. Until recently, the options… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2009
2009
tion, and the results were similar regardless of the stage of disease. Our study shows there are a decreased number of follicular… Expand
  • figure 1
  • figure 2
  • table I
2004
2004
In this report, we describe the case of an 80-year-old woman with unilateral trichomegaly. 
Highly Cited
2003
Highly Cited
2003
The ability of a number of prostaglandin F2α(PGF2α) analogs to mobilize intracellular Ca2+ [Ca2+]i and to compete for [3H]PGF2… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 2
  • figure 3